Molecular interaction study of N1-p-fluorobenzyl-cymserine with TNF-α , p38 kinase and JNK kinase.
Alzheimer's disease (AD) is an age-related neurodegenerative disease distinguished by progressive memory loss and cognitive decline. It is accompanied by classical neuropathological changes, including cerebral deposits of amyloid- beta peptide (Aβ) containing senile plaques, neurofibrillary tangles (NFTs) of phosphorylated tau (p-tau), and clusters of activated glial cells. Postmortem studies strongly support a critical role for neuroinflammation in the pathogenesis of AD, with activated microglia and reactive astrocytes surrounding senile plaques and NFTs. These are accompanied by an elevated expression of inflammatory mediators that further drives Aβ and p-tau generation. Although epidemiological and experimental studies suggested that long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) may lessen AD risk by mitigating inflammatory responses, primary NSAID treatment trials of AD have not proved successful. Elevated systemic butyrylcholinesterase (BuChE) levels have been considered a marker of low-grade systemic inflammation, and BuChE levels are reported elevated in AD brain. Recent research indicates that selective brain inhibition of BuChE elevates acetylcholine (ACh) and augments cognition in rodents free of the characteristic undesirable actions of acetylcholinesterase- inhibitors (AChE-Is). Hence, centrally active BuChE-selective-inhibitors, cymserine analogs, have been developed to test the hypothesis that BuChE-Is would be efficacious and better tolerated than AChE-Is in AD. The focus of the current study was to undertake an in-silico evaluation of an agent to assess its potential to halt the self-propagating interaction between inflammation,Aβ and p-tau generation. Molecular docking studies were performed between the novel BuChE-I, N1-p-fluorobenzyl-cymserine (FBC) and inflammatory targets to evaluate the potential of FBC as an inhibitor of p38, JNK kinases and TNF-α with respect to putative binding free energy and IC50 values. Our in-silico studies support the ability of FBC to bind these targets in a manner supportive of anti-inflammatory action that is subject to molecular dynamics and physiochemical studies for auxiliary confirmation.
Functional Informatics Lab. National Center of Bioinformatics, Quaid-I-Azam University, Islamabad, Pakistan.
Sidra
S
Batool
Muhammad Sulaman
MS
Nawaz
Nigel H
NH
Greig
Mohd
M
Rehan
Mohammad A
MA
Kamal
D000544:Alzheimer Disease / Q000503:physiopathology*; D016229:Amyloid beta-Peptides / Q000096:biosynthesis; D002800:Cholinesterase Inhibitors / Q000494:pharmacology*; D018836:Inflammation Mediators / Q000037:antagonists & inhibitors; D048670:MAP Kinase Kinase 4 / Q000037:antagonists & inhibitors*; D062105:Molecular Docking Simulation; D010830:Physostigmine / Q000031:analogs & derivatives* / Q000737:chemistry; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D048051:p38 Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors*; D016875:tau Proteins / Q000096:biosynthesis
D016229:Amyloid beta-Peptides; D002800:Cholinesterase Inhibitors; D018836:Inflammation Mediators; C584307:N1-p-fluorobenzylcymserine; D014409:Tumor Necrosis Factor-alpha; D016875:tau Proteins; D010830:Physostigmine; D048051:p38 Mitogen-Activated Protein Kinases; D048670:MAP Kinase Kinase 4